315 related articles for article (PubMed ID: 16224215)
21. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
22. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
23. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas.
Feng H; Ghazizadeh M; Konishi H; Araki T
Jpn J Clin Oncol; 2002 Dec; 32(12):525-9. PubMed ID: 12578901
[TBL] [Abstract][Full Text] [Related]
24. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract.
O'Connell FP; Wang HH; Odze RD
Arch Pathol Lab Med; 2005 Mar; 129(3):338-47. PubMed ID: 15737028
[TBL] [Abstract][Full Text] [Related]
25. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
26. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
27. Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands.
Alos L; Lujan B; Castillo M; Nadal A; Carreras M; Caballero M; de Bolos C; Cardesa A
Am J Surg Pathol; 2005 Jun; 29(6):806-13. PubMed ID: 15897748
[TBL] [Abstract][Full Text] [Related]
28. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration.
Chhieng DC; Benson E; Eltoum I; Eloubeidi MA; Jhala N; Jhala D; Siegal GP; Grizzle WE; Manne U
Cancer; 2003 Dec; 99(6):365-71. PubMed ID: 14681945
[TBL] [Abstract][Full Text] [Related]
29. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms.
Goldstein NS; Bassi D; Uzieblo A
Am J Clin Pathol; 2001 Aug; 116(2):246-52. PubMed ID: 11488072
[TBL] [Abstract][Full Text] [Related]
30. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
Hafez NH; Shaaban HM
Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
[TBL] [Abstract][Full Text] [Related]
31. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
32. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
33. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.
Acs G; Pasha T; Zhang PJ
Int J Gynecol Pathol; 2004 Apr; 23(2):110-8. PubMed ID: 15084838
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
35. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
Kim MJ
J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study.
Lau SK; Weiss LM; Chu PG
Am J Clin Pathol; 2004 Jul; 122(1):61-9. PubMed ID: 15272531
[TBL] [Abstract][Full Text] [Related]
37. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
Al-Hussaini M; Stockman A; Foster H; McCluggage WG
Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
[TBL] [Abstract][Full Text] [Related]
38. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors.
Wang J; El-Bahrawy MA
Int J Gynecol Pathol; 2014 Mar; 33(2):166-75. PubMed ID: 24487472
[TBL] [Abstract][Full Text] [Related]
39. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas.
Ramalingam P; Malpica A; Silva EG; Gershenson DM; Liu JL; Deavers MT
Am J Surg Pathol; 2004 Nov; 28(11):1499-505. PubMed ID: 15489654
[TBL] [Abstract][Full Text] [Related]
40. WT1 expression in the female genital tract.
Bárcena C; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):454-65. PubMed ID: 21993272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
